

PARTICULARS TO APPEAR ON THE OUTER PACKAGE (CARDBOARD BOX)}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Zodon 25 mg/ml oral solution

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:

Active substance:

Clindamycin 25.0 mg

(equivalent to 27.15 mg clindamycin hydrochloride)

3. PACKAGE SIZE

20 mL including 3 mL syringe

4. TARGET SPECIES

Cats and dogs

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 28 days.

Once opened, use by:...

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 30°C.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Ceva Sante Animale

14. MARKETING AUTHORISATION NUMBERS

Vm 14966/5060

Vm 14966/3059

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS (BLISTERS)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Zodon 

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Clindamycin 25.0 mg/ml (equivalent to 27.15 mg clindamycin hydrochloride)

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within 28 days.

Once opened, use by....

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Zodon 25 mg/ml Oral Solution for Cats and Dogs

2. Composition

Each ml contains:

Active substance:

Clindamycin 25,0 mg (equivalent to 27,15 mg clindamycin hydrochloride)

Excipients:

Ethanol 96% (E1510) 72 mg

Clear, amber solution.

3. Target species

Cats and dogs

4. Indications for use

Cats:

For the treatment of infected wounds and abscesses caused by clindamycin-susceptible species of *Staphylococcus* spp and *Streptococcus* spp.

Dogs:

- For the treatment of infected wounds, abscesses and oral cavity/dental infections caused by or associated with clindamycin-sensitive species of *Staphylococcus* spp, *Streptococcus* spp, *Bacteroides* spp, *Fusobacterium necrophorum*, *Clostridium perfringens*
- Adjunctive treatment of mechanical or surgical periodontal therapy in the treatment of infections of the gingival and periodontal tissues
- For the treatment of osteomyelitis caused by *Staphylococcus aureus*

5. Contraindications

Do not use in hamsters, guinea pigs, rabbits, chinchillas, horses or ruminants because clindamycin ingestion by these species may cause severe gastrointestinal disorders.

Do not use in cases of hypersensitivity to the active substances, or to any of the excipients

6. Special warnings

Special warnings

None

Special precautions for safe use in the target species

Inappropriate use of the product may increase the prevalence of bacteria resistant to clindamycin. Whenever possible, clindamycin should only be used based on susceptibility testing including the D-zone test.

Official national and local antimicrobial policies should be taken into account when the product is used.

Clindamycin is likely to favour the proliferation of non-susceptible organisms such as resistant *Clostridia* spp and yeasts. In case of secondary infection, appropriate corrective measures should be taken based on clinical observations.

Clindamycin shows parallel-resistance with lincomycin and co-resistance with erythromycin. There is a partial cross-resistance to erythromycin and other macrolides.

In case of administration of high doses of clindamycin or during prolonged therapy of one month or greater, tests for liver and renal functions and blood counts should be performed periodically

In dogs and cats with kidney problems and/or liver problems, accompanied by severe metabolic aberrations, the dose to be administered should be carefully determined and their condition should be monitored by performing appropriate blood tests during treatment.

The use of the product is not recommended in neonates.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Wash hands carefully after use.

People with known hypersensitivity to lincosamides (clindamycin and lincomycin) should avoid contact with the veterinary medicinal product.

Care should be taken to avoid accidental ingestion as this may result in gastrointestinal effects such as abdominal pain and diarrhoea.

In case of accidental ingestion, particularly by a child, or allergic reaction seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

No applicable

Pregnancy and lactation:

While high dose studies in rats suggests that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, the safety of the veterinary medicinal product in pregnant bitches/queens or breeding male dogs/cats has not been established.

Use only according to the benefit/risk assessment by the responsible veterinarian. Clindamycin can pass the placenta and blood-milk barrier. As a consequence, treatment of lactating females can cause diarrhoea in puppies and kittens.

Interaction with other medicinal products and other forms of interaction:

- Aluminium salts and hydroxides, kaolin and Aluminium-Magnesium-Silicate complex may reduce the gastrointestinal absorption of lincosamides. Products containing these substances should be administered at least 2 hours before clindamycin.
- Cyclosporin: clindamycin may reduce levels of this immunosuppressive drug with a risk of lack of activity.
- Neuro-muscular blocking agents: Clindamycin possesses intrinsic neuromuscular blocking activity and should be used cautiously with other neuromuscular blocking agents (curares). Clindamycin may increase neuromuscular blockade.

- Do not use clindamycin simultaneously with chloramphenicol or macrolides as they both target the ribosome 50S subunit and antagonist effects may develop.
- When using clindamycin and aminoglycosides (e.g. gentamicin) simultaneously, the risk of adverse interactions (as acute renal failure) cannot be excluded.

Overdose:

No adverse effects have been reported in dogs after administration of high dosage up to 300 mg/kg clindamycin.

Vomiting, loss of appetite, diarrhoea, leukocytosis and elevated liver enzymes have been observed occasionally. In such cases, discontinue the treatment and administer a symptomatic treatment.

Major Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal product.

7. Adverse events

Cats, dogs:

Very rare
(<1 animal / 10,000 animals treated, including isolated reports):
Vomiting, Diarrhoea

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes

For oral administration only

Recommended dose:

Cats:

- Infected wounds, abscesses: 11mg of clindamycin per kg of body weight per 24h or 5.5 mg /kg per 12h for 7 to 10 days.

The treatment should be stopped if no therapeutic effect is observed after 4 days.

Dogs:

- Infected wounds, abscesses and oral cavity/dental infections: 11 mg clindamycin per kg of body weight per 24h or 5.5 mg /kg per 12h for 7 to 10 days.

The treatment should be stopped if no therapeutic effect is observed after 4 days.

- Treatment of bone infections (osteomyelitis): 11 mg clindamycin per kg of body

weight every 12 hours for a period of 28 days minimum.

The treatment should be discontinued if no therapeutic effect is observed in the first 14 days.

Dosage	Volume to be administered per kg bodyweight
5.5 mg/kg	Corresponding approximately to 0.25 ml per kg
11 mg/kg	Corresponding approximately to 0.5 ml per kg

To ensure administration of a correct dose, body weight should be determined as accurately as possible.

9. Advice on correct administration

A 3 ml graduated syringe is provided to facilitate the administration of the veterinary medicinal product.

The solution is flavoured. The solution can be administered directly into the mouth of the animal or added to a small quantity of food.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 30°C

Once opened use the product within 28 days.

Do not use this veterinary medicinal product after the expiry date which is stated on the vial and carton after "Exp". The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 14966/5060

Vm 14966/3059

Pack sizes:

Cardboard box containing:

- a 20 mL multidose bottle
- a 3 mL syringe

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing Authorisation Holder:

Ceva Sante Animale
8 rue de Logrono
33500 Libourne
France

Contact details to report suspected adverse reactions:

Ceva Animal Health Ltd
Explorer House, Mercury Park
Wycombe Lane, Wooburn Green
High Wycombe
Buckinghamshire
HP10 0HH
United Kingdom
Tel: 00800 35 22 11 51
Email for the reporting of adverse events: pharmacovigilance@ceva.com

Manufacturer responsible for batch release:

Ceva Santé Animale, Boulevard de la Communication, Zone Autoroutière, 53950
LOUVERNE
France

Laboratoires Biové, 3 Rue de Lorraine 62510 Arques France

Ceva Santé Animale, Zone industrielle Très Le bois 22600 Loudéac France

17. Other information

POM-V

 For animal treatment only

Gavin Hall
Approved: 17 October 2025